Comment & Response
July 2015

One-Year Risk of Bleeding With Dabigatran in Patients With Atrial FibrillationPlacing Real-World Results Into Perspective

Author Affiliations
  • 1Pharmacy Department, Jackson Memorial Hospital, Miami, Florida

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2015;175(7):1242-1243. doi:10.1001/jamainternmed.2015.1271

To the Editor The recent retrospective study by Hernandez et al1 reported that while dabigatran was associated with a lower rate of intracranial hemorrhage, the rate of major and gastrointestinal bleeding was higher relative to warfarin users in a Medicare cohort of patients with atrial fibrillation. To further substantiate these results, there are several aspects of this study that merit clarification.

First Page Preview View Large
First page PDF preview
First page PDF preview